CXCL10 and neoplasm: Conversely, in patients with immune-cold tumors and low systemic CXCL10, the goal should be to re-establish local immune dominance, achievable with approaches such as the use of CXCL10-expressing oncolytic viruses and nanoparticle-loaded CXCL10 to generate a localized chemokine gradient that recruits a robust anti-tumor response.